CAP, IASLC, AMP Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer

To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies—the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)—have updated their 2013 evidence-based guideline on molecular testing and targeted therapies in lung cancer.

The Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment.

“Several factors influenced this update, which builds on the guidance we set forth in 2013,” said Neal Lindeman, MD, Director of Molecular Diagnostics at Brigham and Women’s Hospital, Associate Professor of Pathology at Harvard Medical School, and AMP member. “Clinical practice guidelines must continually assess new evidence as it accumulates and consider new testing technologies as they emerge.”

Dr. Lindeman led the international, multidisciplinary panel of expert authors appointed by each of the three organizations. The panel included pathologists, oncologists, pulmonologists, a methodologist, laboratory scientists, and patient representatives who collaborated to develop the guideline following the Institute of Medicine’s evidence-based process.

Important Recommendations

The updated guideline strengthens or reaffirms the majority of the 2013 recommendations for patients with lung adenocarcinoma, and also recommends testing for some new genes. Most notably:

  • Testing for ROS1 mutations is new and strongly recommended for all lung cancer patients regardless of clinical characteristics.
  • Multiplexed genetic sequencing panels (eg, next-generation sequencing testing) are preferred over multiple single-gene tests to identify other treatment options beyond EGFR, ALK, and ROS1; however, single-gene assays are still acceptable.
  • When next-generation sequencing is performed, several other genes are also recommended—BRAF, ERBB2, MET, RET, and KRAS.  However, these genes are not essential when only single-gene tests are performed.
  • Testing in relapse is required for EGFR (T790M), but not for ALK, as the differential sensitivities of second-line ALK inhibitors in the setting of specific acquired mutations in ALK has not yet sufficiently matured and is still investigational.
  • Testing for EGFR T790M in relapse may be done by biopsy or cell-free circulating DNA. However, cell-free DNA is not appropriate for initial diagnosis at this time, unless a tissue or cytology sample cannot be obtained.
  • Previous recommendations, otherwise, were largely reinforced, with some strengthening of evidence that has led to strengthening of the original recommendations. Most notable changes:
    • Inclusion of immunohistochemistry (IHC) for ALK as an alternative to fluorescent in situ hybridization (FISH);
    • oInclusion of any cytology sample with adequate cancer content, as opposed to recommending cell blocks.
    • Opinion is expressed that samples should also be set aside for assays to predict response to immunotherapy (eg, programmed cell death-ligand 1 IHC), but no specific recommendations about how to predict this treatment response were made, and will be the subject of an upcoming guideline.

The complete guideline is available online at the Archives of Pathology & Laboratory Medicine, Journal of Thoracic Oncology, and theJournal of Molecular Diagnostics. Additionally, CAP, IASLC, and AMP developed resources to help pathologists and oncologists review and implement the guideline, including a summary of recommendations, a teaching presentation, and frequently asked questions.   

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.